Imatinib and beyond—the new CML study IVA randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

被引：0
作者：
U. Berger
G. Engelich
A. Reiter
A. Hochhaus
R. Hehlmann
机构：
[1] Universität Heidelberg,III. Medizinische Universitätsklinik, Klinikum Mannheim
来源：
Annals of Hematology | 2004年 / 83卷
关键词：
Chronic myeloid leukemia; Clinical trial; Imatinib; Interferon alpha; Stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：258 / 264
页数：6
相关论文
共 30 条
  • [21] Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
    Smith, B. Douglas
    Rosti, Gianantonio
    Bruemmendorf, Tim
    Roboz, Gail
    Gambacorti-Passerini, Carlo
    Charbonnier, Aude
    Viqueira, Andrea
    Leip, Eric
    Giles, Frank
    Ernst, Thomas
    Castagnetti, Frank
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S240 - S240
  • [22] Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
    Pepe, Sara
    Scalzulli, Emilia
    Colafigli, Gioia
    Di Prima, Alessio
    Mancini, Marco
    Diverio, Daniela
    Latagliata, Roberto
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2261 - 2266
  • [23] Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP)
    Chen, Zi
    Wang, Chun
    Xu, Xiaoping
    Feng, Weiwei
    VALUE IN HEALTH, 2009, 12 : S85 - S88
  • [24] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Branford, Susan
    Mueller, Martin C.
    Kaeda, Jaspal S.
    Foroni, Letizia
    Druker, Brian J.
    Guilhot, Francois
    Larson, Richard A.
    O'Brien, Stephen G.
    Rudoltz, Marc S.
    Mone, Manisha
    Wehrle, Elisabeth
    Modur, Vijay
    Goldman, John M.
    Radich, Jerald P.
    BLOOD, 2010, 116 (19) : 3758 - 3765
  • [25] A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1
    Heibl, Sonja
    Buxhofer-Ausch, Veronika
    Schmidt, Stefan
    Webersinke, Gerald
    Lion, Thomas
    Piringer, Gudrun
    Kuehr, Thomas
    Wolf, Dominik
    Melchardt, Thomas
    Greil, Richard
    Thaler, Josef
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (05) : 792 - 798
  • [26] High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
    W. Deenik
    B. van der Holt
    G. E. G. Verhoef
    A. V. M. B. Schattenberg
    L. F. Verdonck
    S. M. G. J. Daenen
    P. Zachée
    P. H. M. Westveer
    W. M. Smit
    S. Wittebol
    H. C. Schouten
    B. Löwenberg
    G. J. Ossenkoppele
    J. J. Cornelissen
    Annals of Hematology, 2007, 86 : 117 - 125
  • [27] High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia.: A prospective randomized phase III study
    Deenik, W.
    van der Holt, B.
    Verhoef, G. E. G.
    Schattenberg, A. V. M. B.
    Verdonck, L. F.
    Daenen, S. M. G. J.
    Zachee, P.
    Westveer, P. H. M.
    Smit, W. M.
    Wittebol, S.
    Schouten, H. C.
    Lowenberg, B.
    Ossenkoppele, G. J.
    Cornelissen, J. J.
    ANNALS OF HEMATOLOGY, 2007, 86 (02) : 117 - 125
  • [28] Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b and Granulocyte-Macrophage Colony-Stimulating Factor
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Jones, Dan
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Koller, Charles
    Hiteshew, Jody
    Shan, Jenny
    O'Brien, Susan
    Kantarjian, Hagop
    CANCER, 2011, 117 (03) : 572 - 580
  • [29] Imatinib (IMA) Low-Dose Reduction Program (LDRpro) in Chronic Myeloid Leukemia (CML) Ph plus in a Single Reference Institution in Mexico City: Open Prospective Study With 7-Year Follow-up
    Hurtado M, Rafael
    Vargas Viveros, Pablo
    Rios-Calvillo, Daniel
    Carrillo Munoz, Silvia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S347 - S348
  • [30] Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
    Cortes, Jorge E.
    Baccarani, Michele
    Guilhot, Francois
    Druker, Brian J.
    Branford, Susan
    Kim, Dong-Wook
    Pane, Fabrizio
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Kalaycio, Matt
    Moiraghi, Beatriz
    Rowe, Jacob M.
    Tothova, Elena
    De Souza, Carmino
    Rudoltz, Marc
    Yu, Richard
    Krahnke, Tillmann
    Kantarjian, Hagop M.
    Radich, Jerald P.
    Hughes, Timothy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 424 - 430
123